2019 Insurance Manufacturing Provider 
FDA Law Blog
JUNE 3, 2021
Schlanger — While federal efforts to address prescription drug prices are debated, states have continued to pursue their own measures that require drug manufacturers and other entities in the drug supply chain to disclose information about pricing. The 2019 law did not include any penalties for noncompliance with these reporting requirements.
Physician's Weekly
JUNE 19, 2025
In this first installment of a two-part series, “An Arm and a Leg” shares lessons from Bob’s experience navigating a maze of pharmacies and insurance companies to get his daughter the medicine she needs. Bob’s journey here begins in 2019 — the first day of high school for his daughter, Mary. That happens a lot.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
JANUARY 11, 2022
The Court, however, would not dismiss similar allegations as applied to health insurer. Hikma countered that the notice of side effects for patients with CV disease is a warning, not an instruction to use the product in CV patients, and that Hikma has no duty to provide a statement discouraging an infringing use. In the wake of GSK v.
FDA Law Blog
JANUARY 11, 2022
The Court, however, would not dismiss similar allegations as applied to health insurer. Hikma countered that the notice of side effects for patients with CV disease is a warning, not an instruction to use the product in CV patients, and that Hikma has no duty to provide a statement discouraging an infringing use. In the wake of GSK v.
FDA Law Blog
SEPTEMBER 8, 2022
As it stands, the rule allows insurers and pharmacy benefit managers (PBMs) to broadly use copay accumulator programs, which have long been criticized by patient advocacy groups as padding insurers’ pockets while leaving patients high and dry. 156.130(h) to explicitly allow insurers to broadly use copay accumulator programs.
Expert insights. Personalized for you.
52 
Let's personalize your content